Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accumulated Expenses (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Accumulated Expenses for 14 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 2.54% year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Sep 2025, up 2.54%, and an annual FY2024 reading of $5.9 million, up 330.85% over the prior year.
  • Accumulated Expenses was $8.7 million for Q3 2025 at Heron Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $16.3 million in Q2 2022 and bottomed at $1.4 million in Q4 2023.
  • Average Accumulated Expenses over 5 years is $10.2 million, with a median of $9.6 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses crashed 89.78% in 2023, then skyrocketed 330.85% in 2024.
  • Year by year, Accumulated Expenses stood at $15.3 million in 2021, then decreased by 12.1% to $13.4 million in 2022, then plummeted by 89.78% to $1.4 million in 2023, then surged by 330.85% to $5.9 million in 2024, then surged by 48.1% to $8.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for HRTX at $8.7 million in Q3 2025, $6.5 million in Q2 2025, and $6.5 million in Q1 2025.